Analyzing Cost of Revenue: Pharming Group N.V. and Vericel Corporation

Cost of Revenue Trends: Pharming vs. Vericel

__timestampPharming Group N.V.Vericel Corporation
Wednesday, January 1, 2014416727417293000
Thursday, January 1, 2015524785126470000
Friday, January 1, 2016492511828307000
Sunday, January 1, 20171493029730354000
Monday, January 1, 20182537176832160000
Tuesday, January 1, 20192392127437571000
Wednesday, January 1, 20202533823639951000
Friday, January 1, 20212018296650159000
Saturday, January 1, 20221756200054577000
Sunday, January 1, 20232521200061940000
Loading chart...

Unveiling the hidden dimensions of data

Analyzing Cost of Revenue: Pharming Group N.V. vs. Vericel Corporation

In the ever-evolving pharmaceutical landscape, understanding cost dynamics is crucial. From 2014 to 2023, Pharming Group N.V. and Vericel Corporation have shown distinct trends in their cost of revenue. Pharming Group N.V. started with a modest cost of revenue, peaking in 2018 at approximately 25 million, before stabilizing around 20 million in recent years. In contrast, Vericel Corporation's cost of revenue has consistently risen, starting at 17 million in 2014 and reaching a significant 62 million by 2023. This represents a staggering 260% increase over the decade. Such insights highlight Vericel's aggressive growth strategy, while Pharming's cost management reflects a more conservative approach. As the pharmaceutical industry continues to expand, these trends offer a glimpse into the strategic priorities of these companies, providing valuable insights for investors and industry analysts alike.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025